Crinetics Q3 net loss $130.1M; PALSONIFY launched for acromegaly after FDA approval

Crinetics Pharmaceuticals, Inc.

2025-Q3 EPS reported -$3.66 revenue$1,535,000

PALSONIFY (paltusotine) approved by FDA Sept 25 for first-line acromegaly; ~95% of top-priority HCP targets called, ~50% of filled prescriptions reimbursed.
Q3 2025 net loss $130.1M vs $76.8M YoY; R&D $90.5M (+46%), SG&A $52.3M (+102%) driven by launch and pipeline.
Cash, equivalents and investments $1.1B; cash burn guidance $340-370M for 2025; runway into 2029.
Phase 3 CAREFNDR (carcinoid syndrome) and Phase 3 CALM-CAH (CAH) expected to start Q4 2025; Phase 1/2 CRN09682 also Q4.
TSHR antagonist program shifted to alternative candidate; SST3 IND postponed after preclinical data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.